Strategic partnerships Epic Sciences collaborates with leading pharmaceutical companies and major cancer centers worldwide, indicating a strong potential to pursue co-development, licensing, or integration partnerships for their liquid biopsy platform and diagnostic tests.

Clinical applicability Their focus on rare cell identification and circulating tumor cells supports opportunities to target oncology customers seeking non-invasive diagnostics for patient stratification, treatment monitoring, and resistance tracking in metastatic cancer settings.

Financial momentum Recent Series G funding of 24 million and leadership additions signal ongoing growth and market validation, suggesting a favorable backdrop for strategic sales pitches, joint ventures, or channel partnerships with investors or biopharma.

Product expansion Launch of DefineMBC and a CLIA laboratory portfolio demonstrates a path to broaden test offerings, presenting cross-sell or up-sell opportunities to cancer centers and diagnostic labs seeking expanded liquid biopsy solutions.

Market proximity Revenue in the mid single to high single digits with a lean company size implies high-agility sales motions, targeting mid-market cancer centers and specialty labs that can adopt disruptive diagnostics quickly without large enterprise procurement.